Compare ESI & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESI | GKOS |
|---|---|---|
| Founded | 1922 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.3B |
| IPO Year | N/A | 2015 |
| Metric | ESI | GKOS |
|---|---|---|
| Price | $29.74 | $119.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $31.30 | ★ $132.00 |
| AVG Volume (30 Days) | ★ 1.9M | 847.6K |
| Earning Date | 02-17-2026 | 02-17-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $2,499,200,000.00 | $469,820,000.00 |
| Revenue This Year | $2.93 | $32.39 |
| Revenue Next Year | $11.70 | $23.05 |
| P/E Ratio | $30.23 | ★ N/A |
| Revenue Growth | 3.87 | ★ 30.38 |
| 52 Week Low | $16.77 | $73.16 |
| 52 Week High | $30.21 | $161.78 |
| Indicator | ESI | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 63.27 | 54.65 |
| Support Level | $28.56 | $116.73 |
| Resistance Level | $29.88 | $128.84 |
| Average True Range (ATR) | 0.78 | 6.18 |
| MACD | 0.08 | 0.10 |
| Stochastic Oscillator | 77.62 | 71.35 |
Element Solutions Inc is a specialty chemicals company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. The company's reportable segments are Electronics and Industrial & Specialty. The Electronics segment, which generates maximum revenue, researches, formulates, and sells specialty chemicals and process technologies for all types of electronics hardware, from complex printed circuit board designs to semiconductor packaging. This segment's wet chemicals for metallization, surface treatments, and solderable finishes form the physical circuitry pathways, and its assembly materials, such as solder, pastes, fluxes, and adhesives, join those pathways together.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.